These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB. Ann Hematol; 2005 Jan; 84(1):25-32. PubMed ID: 15349754 [Abstract] [Full Text] [Related]
28. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, Illmer T. Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657 [Abstract] [Full Text] [Related]
29. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X. Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638 [Abstract] [Full Text] [Related]
30. Treatment of acute myelogenous leukemia with outpatient azacitidine. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J. Cancer; 2006 Oct 15; 107(8):1839-43. PubMed ID: 16967444 [Abstract] [Full Text] [Related]
33. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF. Cancer; 2008 Feb 01; 112(3):562-71. PubMed ID: 18076087 [Abstract] [Full Text] [Related]
34. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Cancer; 2005 Aug 01; 104(3):547-54. PubMed ID: 15973664 [Abstract] [Full Text] [Related]
35. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S. Haematologica; 2005 Dec 01; 90(12):1617-25. PubMed ID: 16330434 [Abstract] [Full Text] [Related]
39. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Suárez L, Vidriales MB, Moreno MJ, López A, García-Laraña J, Pérez-López C, Tormo M, Lavilla E, López-Berges MC, de Santiago M, San Miguel JF, Orfao A, PETHEMA Cooperative Group. Haematologica; 2005 Jan 01; 90(1):54-9. PubMed ID: 15642669 [Abstract] [Full Text] [Related]
40. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Barragán E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P, Collado R, Sayas MJ, Sanz MA. Haematologica; 2004 Aug 01; 89(8):926-33. PubMed ID: 15339675 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]